Inserm is launching a platform for the clinical evaluation of candidate vaccines against Covid-19 in order to allow “widespread participation of the French population in vaccine trials”.
- Inserm launches a clinical evaluation platform for candidate vaccines against Covid-19
- More than 140 vaccine candidates have been identified and 17 of them are in clinical evaluations
- A scientific committee has been created and a national clinical evaluation platform has been developed
All over the world, researchers are working to develop a vaccine against Covid-19 and 17 of the 140 vaccine candidates are already in clinical evaluations. To summarize the results of these trials, Inserm, with the support of the REACTing network, Public Health France, university hospitals and the college of general medicine teachers, is launching a clinical evaluation platform for candidate vaccines against Covid-19. , baptized COVIREIVAC. The aim is to allow the French population to participate in vaccine trials.
A scientific committee and an evaluation platform
“This project is based on the observation that France’s access to the most promising candidates will only be possible by setting up a ‘one-stop shop’ at the service of industrialists and academics, making it possible to evaluate these products, guarantee the feasibility of clinical trials with the manufacturers concerned and to negotiate production and market conditions”explains Inserm in a communicated.
This initiative involves the creation of a “scientific committee responsible for carrying out a scientific and strategic assessment” of the various candidate vaccines by studying their efficacy, safety and production capacity to identify the most interesting products. The development of a national clinical evaluation platform has also been initiated.
A planned European collaboration
“Dealing with the seriousness of the Covid-19 pandemic means ensuring the widest possible access to the French and European population to future vaccinessays Gilles Bloch, CEO of Inserm. Thanks to an already existing vaccine network, the COVIREIVAC project can give France the necessary attractiveness to guarantee active participation in major vaccine trials and early access to the best vaccine candidates”. In order to be able to extend the device and enable larger-scale clinical trials, Inserm plans to collaborate with other European countries.
With more than 1,500,000 confirmed cases worldwide and 623,461 deaths, Covid-19 continues to progress. According to a recent study, the variant of SARS-CoV-2 currently circulating in Europe and the United States would be more dangerous than the strain that appeared in China.
.
